Moleculera Biosciences

In The News

MAY 23, 2024

Moleculera Biosciences Board of Directors names Healthcare Innovator and Leader Dr. Vijay Aggarwal as Board Chair

Newly appointed Chairman of the Board will provide strategic guidance and enhanced governance and value creation for Moleculera Biosciences

JANUARY 17, 2024

Moleculera Labs Forms Strategic Collaboration with Quest Diagnostics

Companies Collaborate to Broaden Access to Moleculera’s Novel Neuropsychiatric Autoantibody Testing


JANUARY 11, 2024

Moleculera Labs, Inc., Awarded $500,000 Grant Funding to Develop Predictive Treatment Algorithm

Company leveraging strategic alliance w/OKC-based General Genomics to build next-gen predictive treatment model for immune-mediated neuropsychiatric disorders

JANUARY 03, 2024

Moleculera Labs Names Healthcare Industry Veteran Rodney Cotton to Board of Directors

Company readies for growth and expansion of its business to identify and improve chronic immune-mediated disorders


JULY 26, 2022

Moleculera Labs and General Genomics Form Strategic Alliance to Utilize Proprietary AI to Provide Personalized Medicine for Autoimmune Neuropsychiatric Disorders

GGI will bring the power of multiple patent-pending healthcare machine learning (ML) and artificial intelligence (AI) innovations to direct individualized healthcare. Moleculera will contribute its knowledge and expertise in autoimmune neuropsychiatric disorders.

MARCH 27, 2019

U.S. Patent Office Expands Patent Protection for Moleculera Labs’ Diagnostic Panel for Neuropsychiatric Disorders

Cunningham Panel™ Helps Physicians Diagnose Autoimmune-Related Neuropsychiatric Conditions including PANS/PANDAS

SEPTEMBER 12, 2018

Intravenous Immunoglobulin (IVIg) Treatment May Benefit Some Children with Autism Spectrum Disorder

Biomarkers included on Moleculera Labs’ Cunningham Panel™ shown to be helpful in identifying a subset of autistic children likely to benefit from IVIg therapy

NOVEMBER 6, 2017

Moleculera Labs Issued Key U.S. Patent Covering the Company’s Diagnostic Panel for Infection-Induced Autoimmune Neuropsychiatric Disorders

Understanding of PANS/PANDAS Gained via Moleculera’s Cunningham Panel™ May Provide Model for Understanding and Treating Other Chronic Neuropsychiatric Disorders in Adults

JULY 7, 2015

Moleculera Labs Receives Grant from OCAST to Develop Assays to Identify Individuals with Neuropsychiatric Disorders of Autoimmune Origin

This grant supports the development and clinical validation of new diagnostic testing panels to identify autoantibodies directed against neuronal antigens in patients.

APRIL 23, 2013

Innovator of the Year: Moleculera Labs wins overall award

Oklahoma City-based Moleculera Labs received the overall award for its testing of children suffering from forms of neurologic disorders associated with autoimmunity.